培美曲塞/顺铂二线治疗晚期非小细胞肺癌:一例报告及文献复习

Pemetrexed Combined DDP in the Treatment of Advanced Non-small Cell Lung Cancer: A Case Report and Literature Review

背景与目的结合文献复习,探讨二线治疗晚期非小细胞肺癌的价值。方法对重组人血管内皮抑制素联合GC方案一线治疗获完全缓解(complete response,CR)后给予吉非替尼维持治疗,无进展生存期(progression free survival,PFS)10.2个月之后进展的1例转移性非小细胞肺腺癌患者,采用培美曲塞/顺铂二线治疗,随访观察患者PFS和生存时间。结果培美曲塞/顺铂治疗5周期肺原发灶疗效为CR,骨转移灶稳定,PFS为6.6个月,至今已生存22个月,提高了患者的生活质量。结论晚期非小细胞肺腺癌一线治疗/维持治疗后复发或转移,适时启动培美曲塞/顺铂二线治疗可延长患者生存期,提高生存质量。

Background and objective The aim of this study is to integrate with literature review, and explore the value of treatment of advanced non-small cell lung cancer with second line. Methods For the metastatic progressive non-small cell lung adenocarcinoma patient, the evaluation of efficacy for complete response （CR） with endostar combined GC, the sequential treatment with gefitinib, used pemetrexed combined DDP as the second line treatment, followed up and observed with the progression free survival （PFS） and survival time of patient. Results Pemetrexed combined DDP in the treatment of 5 cycles, the evaluation of lung cancer efficacy for CR, bone metastasis was steady, PFS was 6.6 months, survival time is 22 months now, improved the quality of living life. Conclusion For advanced non-small cell lung adenocarcinoma recurrence and metastasis, after the treatment of first line and maintenance therapy, selecting adequately pemetrexed combined DDP, as the second line treatment, can prolong the lifetime and improve the quality of life.